Opyl Limited completed core technology development to minimum viable product (MVP) stage for TrialKey, Opyl's new predictive clinical trial analytics and insights platform. Key development progress included expansion of training data set to >40,000 clinical trials, expanded feature analysis from 150 to 500 features, UX/UI enhancements to target the platform for initial use cases, and improved recall accuracy to best-in-class at ~89%. Strong progress made in commercialisation of TrialKey with market feedback informing primary use cases ­ initially targeting the life sciences investment community and clinical trial designers ­ with discussions currently underway with potential pilot project partners. Significant positive platform feedback received from subject matter experts and market participants in initially identified target sectors, highlighting the value of the TrialKey platform, informing the go-to-market (GTM) strategy and future technology roadmap. Recent development milestones included expanding its feature analysis from 150 to 500. A significant portion of these new features have been made possible through the utilisation of GPT-3's NLP capabilities. This enhancement has facilitated profound insights to be extracted from unstructured text within clinical trials. Notably, the predictive data extracted has resulted in improved accuracy metrics, with the Area Under the Curve (AUC) rising from 0.84 to 0.89. Furthermore, its out-of-sample testing demonstrates enhanced recall at 30%, growing from 79% to 88.8%, underlining the heightened predictive power of its platform. These additional features have also provided more levers for trial designers to consider to increase success rates. Additional commercialisation progress has been made following extensive consultation with subject
matter experts and market participants in the life sciences investment community and clinical trial design sectors. The feedback was significant and positive, validated the platform's value to initial users, and will be used to further inform the GTM strategy and future technology roadmap.